ProQR Therapeutics N.V. (PRQR)

NASDAQ: PRQR · IEX Real-Time Price · USD
2.255
-0.125 (-5.25%)
At close: Mar 28, 2024, 3:58 PM
2.250
-0.005 (-0.22%)
After-hours: Mar 28, 2024, 5:15 PM EDT
-5.25%
Market Cap 187.12M
Revenue (ttm) 10.58M
Net Income (ttm) -31.24M
Shares Out 80.82M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 106,239
Open 2.410
Previous Close 2.380
Day's Range 2.230 - 2.470
52-Week Range 1.110 - 3.290
Beta 0.19
Analysts Strong Buy
Price Target 3.97 (+76.05%)
Earnings Date Mar 13, 2024

About PRQR

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepati... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 18, 2014
Employees 156
Stock Exchange NASDAQ
Ticker Symbol PRQR
Full Company Profile

Financial Performance

In 2023, PRQR's revenue was 9.53 million, an increase of 118.51% compared to the previous year's 4.36 million. Losses were -28.12 million, -56.35% less than in 2022.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for PRQR stock is "Strong Buy." The 12-month stock price forecast is $3.97, which is an increase of 76.05% from the latest price.

Price Target
$3.97
(76.05% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ProQR Announces Year End 2023 Operating and Financial Results

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas...

15 days ago - GlobeNewsWire

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based...

2 months ago - GlobeNewsWire

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based...

2 months ago - GlobeNewsWire

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome

3 months ago - GlobeNewsWire

ProQR Announces Third Quarter 2023 Operating and Financial Results

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) --  ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas...

5 months ago - GlobeNewsWire

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, to...

5 months ago - GlobeNewsWire

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas...

6 months ago - GlobeNewsWire

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas...

7 months ago - GlobeNewsWire

ProQR Announces Second Quarter 2023 Operating and Financial Results

LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies base...

8 months ago - GlobeNewsWire

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU

8 months ago - GlobeNewsWire

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies base...

9 months ago - GlobeNewsWire

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based...

11 months ago - GlobeNewsWire

ProQR Announces Upcoming Investor Conferences in April and May

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas...

1 year ago - GlobeNewsWire

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas...

1 year ago - GlobeNewsWire

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas...

1 year ago - GlobeNewsWire

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, t...

1 year ago - GlobeNewsWire

ProQR to Present at Upcoming Scientific and Industry Conferences

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, t...

1 year ago - GlobeNewsWire

ProQR's stock jumps on expanded RNA deal with Lilly

Shares of ProQR Therapeutics NV PRQR, +1.85% soared 56.3% in premarket trading on Thursday after the company said it expanded an RNA editing deal with Eli Lilly & Co. Inc. LLY, +2.33% aimed at making ...

Other symbols: LLY
1 year ago - Market Watch

ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, to...

1 year ago - GlobeNewsWire

Lilly and ProQR to Expand RNA Editing Collaboration

New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR's Axiomer technology INDIANAPOLIS and LEIDEN, Netherlands and CAMBRIDG...

Other symbols: LLY
1 year ago - PRNewsWire

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transfor...

1 year ago - GlobeNewsWire

ProQR Announces Third Quarter 2022 Operating and Financial Results

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transfor...

1 year ago - GlobeNewsWire

ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) --  ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transfo...

1 year ago - GlobeNewsWire

ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) --  ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transfo...

1 year ago - GlobeNewsWire

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transform...

2 years ago - GlobeNewsWire